Bluejay Therapeutics: Funding, Investors & Team (Oct 2026)
Bluejay Therapeutics is a private biopharmaceutical company that is working on developing treatments for infectious diseases. Their primary focus is on finding a cure for chronic Hepatitis B, which is a prevalent disease globally and has a critical need for medical solutions. Bluejay is progressing with two unique methods that offer a high chance of achieving a functional cure: top-grade human IgG1 anti-HBs monoclonal antibodies and novel HBsAg oral small molecule inhibitors. The company is hopeful that by diminishing hepatitis B surface antigen levels and reinstating adaptive immunity, patients can achieve a functional cure.
Bluejay Therapeutics has raised $182M across 1 funding round on record, the most recent a Series C of $182M announced in May 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Bluejay Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2024.
Bluejay Therapeutics Funding Rounds
Bluejay Therapeutics Founders and Leadership Team
Contact details for the Bluejay Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Bluejay Therapeutics Funding Compared to Other Biotechnology Startups
Bluejay Therapeutics' latest round of $182M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Bluejay Therapeutics in Biotechnology and San Francisco
Companies Similar to Bluejay Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Bluejay Therapeutics Funding FAQs
What does Bluejay Therapeutics do?
Bluejay Therapeutics is a private biopharmaceutical company that is working on developing treatments for infectious diseases. Their primary focus is on finding a cure for chronic Hepatitis B, which is a prevalent disease globally and has a critical need for medical solutions. Bluejay is progressing with two unique methods that offer a high chance of achieving a functional cure: top-grade human IgG1 anti-HBs monoclonal antibodies and novel HBsAg oral small molecule inhibitors. The company is hopeful that by diminishing hepatitis B surface antigen levels and reinstating adaptive immunity, patients can achieve a functional cure.
How much funding has Bluejay Therapeutics raised?
Bluejay Therapeutics has raised $182M across 1 round on record. The most recent is a Series C of $182M announced in May 2024.
When did Bluejay Therapeutics last raise funding?
Bluejay Therapeutics' most recent funding round on record is a Series C of $182M, announced in May 2024.
Who founded Bluejay Therapeutics?
FundedIQ lists Keting Chu (Founder) at Bluejay Therapeutics.
Where is Bluejay Therapeutics headquartered?
Bluejay Therapeutics is based in San Francisco, California, United States.
How many employees does Bluejay Therapeutics have?
Bluejay Therapeutics is in the 11-50 employee band.
How does Bluejay Therapeutics' funding compare to other Biotechnology startups?
Bluejay Therapeutics' latest round of $182M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Bluejay Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bluejay Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.